



Ref: JSTL/BOD/BSE/2024-25/May24

Date: May 30, 2024

To
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001.
(BSE Scrip Code: 538837)

Dear Sir/Madam,

Unit: Jeevan Scientific Technology Limited (Scrip Code: 538837)

Ref: Board Meeting Intimation Dated 21-05-2024

Sub: Outcome of Board Meeting for the quarter and year ended 31.03.2024 under regulation 30 and 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.

Dear Sir/ Madam,

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Jeevan Scientific Technology Limited** at its meeting held on Thursday, the 30th day of May, 2024 at 11:30 a.m. at registered office of the Company for the quarter and financial year ended 31.03.2024 considered and approved the following:

1. Audited Financial Results (standalone and consolidated) for the quarter and financial year ended 31.03.2024. **(Attached)**
2. Auditors Report (standalone and consolidated) along with declaration of unmodified opinion for the financial year 31.03.2024. **(Attached)**
3. Re Appointment of Mr. Nageswar Rao Yarllagadda as Executive Director of the Company for a period of 3 years w.e.f. 23.06.2024, subject to the approval of members in the ensuing general meeting. (Brief Profile attached as **Annexure A**)
4. Re Appointment of Mr. Jeevan Krishna Kuchipudi as Executive Director and Chief Financial officer of the Company for a period of 3 years w.e.f. 14.02.2025, subject to the approval of members in the ensuing general meeting. (Brief Profile attached as **Annexure A**)



5. Appointment of M/s. KP & Associates, Chartered Accountants as Internal Auditors for FY 2024-25. (Brief Profile attached as **Annexure B**)
6. Appointment of Ms. Aakanksha Sachin Dubey, Company Secretary as Secretarial Auditors for FY 2024-25. (Brief Profile attached as **Annexure B**)
7. To take note of Resignation of Mrs. Sharvari Swapnil Shinde, Company Secretary and Compliance officer of the Company w.e.f. 31.03.2024. (Brief details attached as **Annexure C**)
8. Appointment of Mr. Krishna Sainadh Kodati as Company Secretary and Compliance officer of the Company w.e.f. 30.05.2024. (Brief Profile attached as **Annexure C**)
9. Reappointment of Mr. Thammareddy Ravi, Director of the Company, Retire by rotation. (Brief Profile attached as **Annexure D**)
10. Reappointment of Mr. Nageswar Rao Yarllagadda, Director of the Company, Retire by rotation. (Brief Profile attached as **Annexure D**)
11. Granting of 1,50,000 options to the eligible employees of M/s. Nayas Laboratories Private Limited, Subsidiary Company pursuant to JSTL ESOP Scheme 2016 as recommended by Nomination and Remuneration Committee. (**Refer Annexure – E**)
12. Acquisition of 70% equity stake in M/s. SM Therapeutics Private Limited (**Refer Annexure – F**)
13. Notice of the Annual General Meeting (AGM) and Directors Report for the financial year 2023-24.
14. Annual General Meeting for the FY 2023-24 is scheduled to be held on Friday, 09.08.2024 at 10:00 a.m. through video conference or other audio-visual means.

The meeting concluded at 03.00 P.M.



This is for the information and records of the Exchange, please.

Thanking You,

Yours faithfully,

For Jeevan Scientific Technology Limited

Krishna Kishore Kuchipudi
Vice Chairman and Managing Director
(DIN: 00876539)



Annexure A

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated July 13, 2023]

Particulars	Mr. Nageswar Rao Yarllagadda	Mr. Jeevan Krishna Kuchipudi
Reason for change viz. appointment, resignation, removal, death or otherwise	Reappointment of Mr. Nageswar Rao Yarllagadda as Executive Director of the Company for period of 3 years w.e.f. 23.06.2024.	Reappointment of Mr. Jeevan Krishna Kuchipudi as Executive Director of the Company for period of 3 years w.e.f. 14.02.2025.
Date of appointment & Terms of appointment	Reappointment of Mr. Nageswar Rao Yarllagadda as Executive Director of the Company for period of 3 years w.e.f. 23.06.2024.	Reappointment of Mr. Jeevan Krishna Kuchipudi as Executive Director of the Company for period of 3 years w.e.f. 14.02.2025.
Brief Profile	Mr. Y. Nageswara Rao is an experienced professional in the areas of Management, Operations, Finance Marketing and Administration. Currently a Director of Sri Surya Wheels Private Limited, he has an overall experience of over 30 years successfully managing multiple organisations - Sri Surya Automobiles, Sri Surya Transport Corporation, Sri Surya Wheels Private Limited, Sri Surya Electronics and Home Appliances. He has gained multiple awards in the field of marketing and has rich experience in managing multiple teams across various levels and locations.	Mr. Jeevan Krishna Kuchipudi is a passionate leader and an enthusiastic honors business graduate with diverse global experience, exceptionally in IT, Operations and Finance. He pursued undergraduate program for engineering in Computer Science from VNR Vignana Jyothi Institute of Engineering & Technology and Masters in Business Administration (MBA) in Finance from San Diego State University.
Disclosure of relationships between directors (in case of appointment of a	Mr. Nageswar Rao Yarllagadda is not related to any of the Directors or Key Managerial Personnel of the Company.	Mr. Jeevan Krishna Kuchipudi is not related to any of the Directors or Key Managerial Personnel of the



director)		Company except being related to Mr. Krishna Kishore Kuchipudi, Managing Director and Mrs. Snigdha Mothukuri, Executive Director and CEO.
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref. no NSE/CML/2018/24 dated June 20, 2018	Mr. Nageswar Rao Yarllagadda is not de-barred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.	Mr. Jeevan Krishna Kuchipudi is not de-barred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.



Annexure B

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated July 13, 2023]

Particulars	Internal Auditor	Secretarial Auditors
Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of M/s. KP & Associates, Chartered Accountants as Internal Auditor of the Company.	Appointment of Mrs. Aakanksha Sachin Dubey, Practicing Company Secretary as Secretarial Auditors of the Company.
Date of appointment & Terms of appointment	For the Financial Year 2024-25.	For the Financial Year 2024-25.
Brief Profile	M/s. KP & Associates, Chartered Accountants, having over 14 years of experience in the areas of Audit and Assurance, Direct and Indirect Taxation, Financial Services, Corporate Advisory, Corporate Laws and Secretarial Practice, etc.	Mrs. Aakanksha Sachin Dubey, Practicing Company Secretary having wide client base ranging from Listed and Unlisted Companies and handled numerous corporate actions such as Initial Public Offers (IPOS), Takeovers, preferential issues, bonus issues, rights issues, buyback, mergers and demergers, delisting, revocation of suspension, corporate restructuring and so on.
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable



Annexure C

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated July 13, 2023]

Particulars	Mrs. Sharvari Swapnil Shinde	Mr. Krishna Sainadh Kodati
Reason for change viz. appointment, resignation, removal, death or otherwise	Resignation of Mrs. Sharvari Swapnil Shinde, Company Secretary and Compliance officer of the Company	Appointment of Mr. Krishna Sainadh Kodati as Company Secretary and Compliance officer of the Company
Date of appointment & Terms of appointment	Resignation of Mrs. Sharvari Swapnil Shinde, Company Secretary and Compliance officer of the Company w.e.f. 31.03.2024	Appointment of Mr. Krishna Sainadh Kodati as Company Secretary and Compliance officer of the Company w.e.f. 30.05.2024
Brief Profile	Not Applicable	Mr. Krishna Sainadh Kodati is an associate member of the Institute of Company Secretaries of India having membership No. A69904 and he has knowledge and experience in corporate legal & secretarial services.
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable	Mr. Krishna Sainadh Kodati is not related to any of the Directors or Key Managerial Personnel of the Company.



Annexure D

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated July 13, 2023]

Particulars	Mr. Thammareddy Ravi	Mr. Nageswar Rao Yarllagadda
Reason for change viz. appointment, resignation, removal, death or otherwise	Reappointment of Mr. Thammareddy Ravi, Director of the Company, Retire by rotation.	Reappointment of Mr. Nageswar Rao Yarllagadda, Director of the Company, Retire by rotation.
Date of appointment & Terms of appointment	Reappointment of Mr. Thammareddy Ravi, Director of the Company, Retire by rotation, subject to the approval of members in the ensuing AGM.	Reappointment of Mr. Nageswar Rao Yarllagadda, Director of the Company, Retire by rotation, subject to the approval of members in the ensuing AGM.
Brief Profile	Mr. Ravi Babu completed his MBA Degree from Symbiosis Institute of Management, Pune, he has over 14 years of experience in freelancing, advertising and consulting computer graphics and also worked as Director of Cinematography in Indian Broadcasting Company at New York for 4 Years. His exposure includes-Advanced Cinematographic film in Television Workshops, Rockport Main, USA and Advanced Online Editing Systems Management from Sony Institute of Applied Video Technology, Sam Jones, California, USA.	Mr. Y. Nageswara Rao is an experienced professional in the areas of Management, Operations, Finance Marketing and Administration. Currently a Director of Sri Surya Wheels Private Limited, he has an overall experience of over 30 years successfully managing multiple organizations - Sri Surya Automobiles, Sri Surya Transport Corporation, Sri Surya Wheels Private Limited, Sri Surya Electronics and Home Appliances. He has gained multiple awards in the field of marketing and has rich experience in managing multiple teams across various levels and locations.



Disclosure of relationships between directors (in case of appointment of a director)	Mr. Thammareddy Ravi is not related to any of the Directors or Key Managerial Personnel of the Company.	Mr. Nageswar Rao Yarllagadda is not related to any of the Directors or Key Managerial Personnel of the Company.
Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 and the National Stock Exchange of India Ltd with ref. no NSE/CML/2018/24 dated June 20, 2018	Mr. Thammareddy Ravi is not de-barred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.	Mr. Nageswar Rao Yarllagadda is not de-barred from holding office of Director by virtue of any Securities and Exchange Board of India (SEBI) order or any other such statutory authority.



Annexure E

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated July 13, 2023]

In accordance with the provisions of the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), we hereby inform you that a meeting of the Board of Director of Jeevan Scientific Technology Limited (the "Company") has approved the recommendation of Nomination and Remuneration Committee for granting of 1,50,000 Employee Stock Options ("Options") convertible into equal number of Equity Shares of the Company at a face value of Rs. 10/- each, to the eligible employees of M/s. Nayas Laboratories Private Limited, Subsidiary Company under the JSTL Employee Stock Option Scheme - 2016 ("Scheme").

The terms of the grant, inter-alia, are as under:

S.No	Particulars	Details
1.	Brief details of options granted	Grant of 1,50,000 options to eligible employees. Effective grant date being 30.05.2024.
2.	Whether the scheme is in terms of SEBI (SBE) Regulations, 2014 (if applicable)	Employee Stock Options Scheme 2016 has been formulated and adopted by the Company in terms of the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014.
3.	Total number of shares covered by these options	1,50,000 Equity Shares of face value Rs. 10 each. (Each Option is convertible into one Equity Share of the Company).
4.	Pricing Formula	Under this Scheme, the exercise price of the Shares will be decided by NRC.
5.	Options Vested	The said options shall vest as per the policy decided by the NRC but not before 1 year from the date of grant.
6.	Time within which option may be exercised	The exercise period shall be 1 – 5 years from the date of last vesting.
7.	Options exercised	Not applicable
8.	Money realized by exercise of Options	Not Applicable as this communication is pertaining to grant of Options under the Scheme.
9.	The total number of Shares arising as a result of exercise of Option	Not Applicable as this communication is pertaining to grant of Options under the Scheme.
10.	Options lapsed	Not Applicable as this communication is pertaining to grant of Options under the Scheme.
11.	Variation in terms of Options	Not Applicable



12.	Brief details of significant terms	The Scheme is administered by the Nomination and Remuneration Committee. The grant of Options is based upon the eligibility criteria as mentioned in the Scheme. The granted Options, once vested shall entitle the Option holder to acquire equal number of Equity Shares, upon payment of exercise price and applicable taxes in accordance with terms and conditions of the Scheme. The granted Options shall vest within minimum period of 1 year and maximum period of 5 years from the date of grant. The Exercise Price of the Options granted to an Eligible Employee shall be determined by the Nomination and Remuneration Committee subject to conforming to applicable accounting policies. Provided, however, the Exercise Price shall in no event be less than the face value of the Shares.
13.	Subsequent changes or cancellation or exercise of such Options.	Not Applicable as this communication is pertaining to grant of Options under the Scheme.
14.	Diluted earnings per share pursuant to the issue of equity shares on exercise of Options.	Not Applicable as this communication is pertaining to grant of Options under the Scheme.



Annexure F

[Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with clause 7 of Para A of Annexure I of SEBI Circular dated July 13, 2023]

S. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.;	SM Therapeutics Private Limited
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	<p>Yes.</p> <ul style="list-style-type: none">Mr. K. Krishna Kishore and Mrs. K. Vanaja are the shareholders of the Company for 100% shareholding.As on date the Company has three directors of which two directorships are held by Mr. K. Krishna Kishore and Mrs. K. Vanaja. <p>The above said two shareholders are also promoters of the investing Company (Jeevan Scientific Technology Limited). Mr. K. Krishna Kishore is a Common Director on the Boards of both the investing and investee companies.</p>
3.	Industry to which the entity being acquired belongs;	Pharma Sector
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	As part of diversification and expansion of the existing business, the Company intends to acquire the companies engaged in pharma sector which also creates synergy for the clinical trials business undertaken by the Company.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	NIL
6.	Indicative time period for completion of the acquisition;	6 months from the date of Board Meeting of Jeevan Scientific Technology Limited.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same;	Cash
8.	Cost of acquisition and/or the price at which the shares are acquired;	Rs. 70.00 Lakhs
9.	Percentage of shareholding / control acquired and / or	70 % on the post issue paid capital of M/s. SM Therapeutics Private Limited



	number of shares acquired;	
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	SM Therapeutics Private Limited was incorporated on 18/01/2024 with paid up capital of Rs. 25,00,000 divided into 2,50,000 equity shares Rs. 10/- each. The objects of the Company include Research and development in Pharmaceuticals, Specialty chemicals, cosmetics, natural products, providing scientific consultancy services, import and export of chemicals, trading and manufacturing of specialty chemicals, glasses and lab equipments and establishment of Research and Development centres.



Ref: JSTL/BOD/BSE/2024-25/May24

Date: May 30, 2024

**To
The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001.
(BSE Scrip Code: 538837)**

Dear Sir/Madam,

Unit: Jeevan Scientific Technology Limited (Scrip Code: 538837)

Sub: Declaration pursuant to regulation 33 (3) (d) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion.

I, K. Krishna Kishore, Vice Chairman and Managing Director of Jeevan Scientific Technology Limited hereby declare that, the Statutory Auditors of the company, M/s. Pavuluri & Co have issued an Audit Report with unmodified/unqualified opinion on Standalone and Consolidated Audited Financial Results of the company for the quarter and year ended 31st March, 2024.

This declaration is issued in compliance of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you.

Yours faithfully,
For Jeevan Scientific Technology Limited

**K. Krishna Kishore
Vice Chairman and Managing Director
(DIN: 00876539)**

Jeevan Scientific Technology Limited
 CIN:L72200TG1999PLC031016
 Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
Statement of Standalone Audited financial results for the quarter and Year ended 31 March 2024
 All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	Quarter Ended				Year Ended	
	31 March 2024	31 December 2023	31st March 2023	31 March 2024	31 March 2023	
	Audited	Unaudited	Audited	Audited	Audited	
Revenue from operations	992.02	1,012.75	792.51	3,850.17	3,617.80	
(a) Net sales/Income from operations	992.02	1,012.75	792.51	3,850.17	3,617.80	
Total revenue from operation	25.44	(11.59)	26.24	69.00	106.19	
II Other Income	1,017.46	1,001.16	818.75	3,919.17	3,723.99	
III Total Income (I+II)						
IV Expenses	101.43	85.62	73.64	368.48	245.54	
(a) Cost of materials consumed	-	-	-	-	54.65	
(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	391.22	389.07	421.24	1,517.82	1,486.56	
(c) Employee benefits expense	16.19	13.11	25.05	73.28	94.76	
(d) Finance costs	140.57	134.54	136.96	554.68	502.36	
(e) Depreciation and Amortization expense	444.38	448.86	401.74	1,527.83	1,701.97	
(f) Other Expenses	1,093.79	1,051.20	1,058.63	4,042.09	4,085.84	
Total Expenses (IV)	(76.33)	(50.04)	(239.88)	(122.92)	(361.85)	
V Profit (Loss) before Tax (III-IV)						
VI Tax Expenses	-	(0.53)	-	-	49.55	
(a) Current tax	-	-	49.55	(17.96)	(111.10)	
(b) Adjustment of tax relating to earlier period	(2.65)	(10.16)	(64.48)	(17.96)	(61.55)	
(c) Deferred tax	(2.65)	(10.69)	(14.93)	(17.96)	(61.55)	
Total tax expense	(73.68)	(39.35)	(224.95)	(104.96)	(300.30)	
VII Profit(Loss) for the period/year (V-VI)						
VIII Other Comprehensive Income						
A (i) Items that will not be reclassified subsequently to profit or loss	5.80	-	(5.78)	2.90	(11.49)	
(ii) Income tax relating to items that will not be reclassified	(1.61)	-	2.89	(0.81)	2.89	
B (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	
IX Total other comprehensive income(loss) for the period	4.19	-	(2.89)	2.09	(8.60)	
Total Comprehensive Income for the period (VII+IX)	(69.49)	(39.35)	(227.84)	(102.87)	(308.90)	
X Total Comprehensive Income (Face value of Rs. 10/- each)	1,548.02	1,548.02	1,548.02	1,548.02	1,548.02	
XI Paid Up equity share capital (Face value of Rs. 10/- each)	-	-	-	3,332.13	3,283.58	
XII Other equity						
Earnings per equity share (of Rs. 10/- each) (not annualized for the quarters)						
a) Basic	(0.48)	(0.25)	(1.45)	(0.68)	(1.96)	
b) Diluted	(0.48)	(0.25)	(1.45)	(0.68)	(1.96)	



[Handwritten signature]

Notes to the Audited financial results

- 1 The above Audited standalone financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act 2013 with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
- 2 The above Audited standalone results have been reviewed by the Audit Committee at its meeting held on 30th May 2024 and approved by the Board of Directors of the Company at their meeting held on 30th May 2024
- 3 The Statutory Auditors of the Company have audited the above audited standalone financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) regulations, 2015.
- 4 Employee benefit expenses for the Quarter ending 31 March 2024 includes Rs. 37.85 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".
- 5 The company operates in one reportable business segment i.e. Clinical Research Services. Hence segment reporting as per Ind AS 108 is not applicable.
- 6 The results for the Quarter and Year ended 31 March 2024 are also available on website of BSE Limited and on the Company's website.
- 7 The figures for the quarter ended March 31, 2024 and 2023, represent the differences between the audited figures in respect of full financial years and the published figures for the nine months ended December 31, 2023 and 2022, respectively which were subject to limited review.

for Jeevan Scientific Technology Limited


K. Krishna Kishore
Vice Chairman & Managing Director
(DIN:00876539)



Place: Hyderabad.
Date:30 May 2024

Jeevan Scientific Technology Limited

CIN:L72200TG1999PLC031016

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

Statement of Standalone Audited Assets and Liabilities

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

	As at 31 March 2024	As at 31 March 2023
	Audited	Audited
Assets		
(1) Non-current Assets		
a) Property, plant and equipment	1,331.83	1,550.26
b) Other intangible assets	553.41	603.58
c) Right of use assets	135.08	249.24
d) Financial Assets		
i) Investments	200.00	200.00
ii) Other financial assets	59.57	56.41
e) Other non current assets	1,207.54	857.54
f) Deferred tax asset (net)	81.11	63.95
	3,568.54	3,580.98
(2) Current Assets		
a) Inventories	100.79	87.16
b) Financial Assets		
i) Trade receivables	1,193.02	1,168.19
ii) Cash and cash equivalents	51.00	612.25
iii) Other financial assets	397.29	527.90
c) Current tax assets (net)	452.21	275.37
d) Other current assets	228.39	123.82
	2,422.70	2,794.68
	5,991.24	6,375.66
TOTAL ASSETS		
Equity and Liabilities		
Equity		
a) Equity Share Capital	1,548.02	1,548.02
b) Other Equity	3,332.13	3,283.58
	4,880.15	4,831.60
Liabilities		
(1) Non-current Liabilities		
a) Financial liabilities		
(i) Borrowings	177.21	321.35
(ii) Lease liabilities	75.86	148.17
(iii) Other financial liabilities	40.78	30.95
b) Provisions		
	293.85	500.47
(2) Current Liabilities		
a) Financial liabilities		
i) Borrowings	246.71	292.67
ii) Lease liabilities	80.82	121.68
iii) Trade payables		
(a) Total outstanding dues of micro, small and medium enterprises	36.94	69.14
(b) Total Outstanding dues of creditors other than micro, small and medium enterprises	149.42	193.76
iv) Other financial liabilities	104.09	103.11
b) Other current liabilities	198.02	262.13
c) Provisions	1.24	1.10
d) Current tax liabilities (net)	-	-
	817.25	1,043.59
	5,991.24	6,375.66
TOTAL EQUITY AND LIABILITIES		

for Jeevan Scientific Technology Limited

Place: Hyderabad.
Date: 30 May 2024

K. Krishna Kishore
Vice Chairman & Managing Director
(DIN:00876539)



Jeevan Scientific Technology Limited

CIN:L72200TG1999PLC031016

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.

Statement of Standalone Audited Cash Flows

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

S.No	Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
A.	Cash flow from operating activities	(122.93)	(361.86)
	Net Profit/(loss) before tax		
	Adjustments for:		
	Depreciation and amortisation expenses	554.69	502.36
	Dividend received	(11.79)	(10.50)
	Interest received	(40.81)	(83.19)
	Fair value (gain)/loss on financial assets measured at amortized cost, net	(3.51)	(3.50)
	Share based payments to employees	151.41	247.94
	Net foreign exchange loss/(gain)	(2.81)	(2.85)
	Finance cost	62.53	94.76
	Operating profit before working capital changes	586.78	383.16
	Changes in Working Capital		
	Inventories	(13.64)	58.40
	Trade receivables	(22.02)	(404.36)
	Current and non current financial assets	130.97	248.85
	Other current and non current assets	(104.57)	136.99
	Trade payables	(76.54)	62.69
	Other financial liabilities	0.98	(223.94)
	Other liabilities	(64.11)	(112.15)
	Provisions	12.88	(503.02)
	Cash generated from operations before Tax	450.73	(353.37)
	Taxes Paid	(176.84)	(275.37)
	Net cash from operating activity	273.89	(628.74)
B.	Cash flow from investing activities		
	Purchase of property, plant and equipment including capital advances and capital creditors	(521.93)	(625.92)
	Investment in subsidiaries	-	(200.00)
	Dividend Received	11.79	10.50
	Movement in other bank balances	-	5.24
	Interest Received	40.81	83.19
	Net cash used in investing activity	(469.33)	(727.00)
C.	Cash flow from financing activity		
	Repayment of non current borrowings	(141.36)	(244.97)
	Repayment of current borrowings	(48.74)	(395.40)
	Interest paid	(62.53)	(94.76)
	Dividend paid	-	(183.62)
	Proceeds from issuance of Equity Shares (ESOPS Exercise)	-	17.88
	Repayment of principle portion of lease liability	(113.16)	(102.48)
	Net cash generated in financing activity	(365.79)	(1,003.35)
	Net increase in cash and cash equivalents (A+B+C)	(561.24)	(2,359.09)
	Cash and cash equivalents at the beginning of the year/period	612.25	2,971.33
	Cash and cash equivalents at the end of the year/period	51.00	612.25

for Jeevan Scientific Technology Limited

Place: Hyderabad.
Date:30 May 2024


K. Krishna Kishore
 Vice Chairman & Managing Director
 (DIN:00876539)



JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
CIN:L72200TG1999PLC031016

Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
Statement of consolidated audited financial results for the quarter and Year ended 31 March 2024

(All Amounts in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	Quarter Ended		Year Ended	
	31 March 2024 Audited	31 December 2023 Unaudited	31 March 2023 Audited	31 March 2024 Audited
Revenue from operations				
(a) Net sales/Income from operations	1,106.89	1,012.75	792.51	3,965.04
Total revenue from operation	1,106.89	1,012.75	792.51	3,965.04
II Other Income	23.27	-1.40	27.47	67.46
Total income (I+II)	1,130.16	1,001.35	819.98	4,032.51
III Total income (I+II)	1,130.16	1,001.35	819.98	4,032.51
IV Expenses				
(a) Cost of materials consumed	114.64	85.62	73.64	381.70
(b) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
(c) Employee benefits expense	428.31	369.41	421.26	1,555.85
(d) Finance costs	32.90	14.64	27.50	96.80
(e) Depreciation and Amortization expense	163.93	139.50	141.92	592.93
(f) Other Expenses	466.31	456.44	401.94	1,565.61
Total Expenses (IV)	1,206.09	1,065.61	1,066.26	4,192.90
V Profit/ (Loss) before tax (III-IV)	(75.93)	(64.26)	(246.28)	(160.39)
VI Tax expenses				
(a) Current tax	-	(0.53)	-	-
(b) Adjustment of tax relating to earlier period	(2.69)	(15.01)	49.55	(27.67)
(c) Deferred tax	-	-	(64.72)	-
Total Tax Expenses (VI)	(2.69)	(15.01)	(15.17)	(27.67)
VII Profit/(Loss) for the period/year	(78.62)	(79.27)	(261.43)	(188.06)
VIII Other Comprehensive Income				
A (i) Items that will not be reclassified subsequently to profit or loss	5.81	-	(5.78)	2.90
(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	(1.62)	-	2.89	(0.81)
B (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Total Other Comprehensive Income (VIII)	4.19	-	(2.89)	2.09
IX Total Comprehensive Income for the period/year	(69.05)	(48.72)	(234.00)	(130.62)
Total Comprehensive Income for the period/year	(69.05)	(48.72)	(234.00)	(130.62)



[Signature]

X	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,548.02	1,548.02	1,548.02	1,548.02	1,548.02	1,548.02
XI	Other equity excluding revaluation reserve	-	-	-	-	3,294.82	3,270.94
XII	Earnings per Equity share						
	a) Basic (Amount in Rupees)	(0.47)	(0.31)	(1.49)	(0.86)	(2.00)	(2.00)
	b) Diluted (Amount in Rupees)	(0.47)	(0.31)	(1.49)	(0.86)	(2.00)	(2.00)
			Not annulsed				
XIII	Net profit attributable to:						
	Owners of the company	(73.29)	(47.68)	(230.38)	(129.64)	(305.74)	(305.74)
	Non-Controlling interest	0.05	(1.04)	(0.73)	(3.08)	(0.73)	(0.73)
XIV	Other comprehensive income attributable to:						
	Owners of the company	4.19	-	(2.89)	2.09	(8.60)	(8.60)
	Non-Controlling interest	-	-	-	-	-	-
XV	Total comprehensive income attributable to:						
	Owners of the company	(69.10)	(47.68)	(233.27)	(127.54)	(314.34)	(314.34)
	Non-Controlling interest	0.05	(1.04)	(0.73)	(3.08)	(0.73)	(0.73)

Notes to the Audited financial results

- The above Audited Consolidated financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act 2013 with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India.
- The above Audited Consolidated results have been reviewed by the Audit Committee at its meeting held on 30th May 2024 of the board and approved by the Board of Directors of the Company at their meeting held on 30th May 2024
- The Statutory Auditors of the Company have audited the above audited Consolidated financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) regulations, 2015.
- Employee benefit expenses for the Quarter ending 31 March 2024 includes Rs.37.85 Lakhs towards ESOP Scheme 2016 provided as per " Ind AS 102 - Share Based Payments".
- The company operates in one reportable business segment i.e. Clinical Research Services. Hence segmental reporting as per Ind AS 108 is not applicable.
- The results for the Quarter and Year ended 31 March 2024 are also available on website of BSE Limited and on the Company's website.
- The figures for the quarter ended March 31, 2024 and 2023, represent the differences between the audited figures in respect of full financial years and the published figures for the nine months ended December 31, 2023 and 2022, respectively which were subject to limited review.

for Jeewan Scientific Technology Limited

K. Krishna Kishore

Vice Chairman & Managing Director

(DIN:00876539)



Place: Hyderabad.

Date: 30 May 2024

Jeevan Scientific Technology Limited
CIN:L72200TG1999PLC031016
Registered Office:Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda
Post, Hyderabad-500008.
Statement of Consolidated Audited Assets and Liabilities
(Amount in Indian rupees lakhs, except share data and where otherwise stated)

Particulars	As at	As at
	31 March 2024	31 March 2024
	Audited	Audited
Assets		
(1)Non-current Assets		
a) Property, plant and equipment	1,878.76	1,550.26
b) Other intangible assets	553.41	603.58
c) Capital work in progress	281.17	190.36
d) Right of use assets	234.30	343.47
e) Financial Assets		
i)Other financial assets	72.98	64.03
f) Other non current assets	1,207.54	857.54
g) Deferred tax asset (net)	91.06	64.19
	4,319.22	3,673.44
(2)Current Assets		
a) Inventories	108.99	87.16
b) Financial Assets		
i) Trade receivables	1,229.13	1,168.19
ii) Cash and cash equivalents	54.45	683.38
iii)Other financial assets	298.35	527.90
c) Current tax assets (Net)	452.96	275.46
d) Other current assets	323.46	176.76
	2,467.34	2,918.84
	6,786.56	6,592.29
TOTAL ASSETS		
Equity and Liabilities		
Equity		
a) Equity share capital	1,548.02	1,548.02
b) Other equity	3,294.82	3,270.94
	4,842.84	4,818.96
Total equity		
Non controlling interest	20.29	23.37
	4,863.12	4,842.33
Liabilities		
(1) Non-current Liabilities		
a) Financial liabilities		
(i) Borrowings	804.95	351.35
(ii) Lease liabilities	156.90	228.70
(iii) Other financial liabilities	40.78	30.95
b) Provisions		
	1,002.63	611.00
(2) Current Liabilities		
a) Financial Liabilities		
i) Borrowings	273.29	292.67
ii) Lease liabilities	105.81	136.79
iii) Trade payables		
(a) Total outstanding dues of micro, small and medium enterprises	57.53	69.14
(b) Total outstanding dues of Creditors other than micro,small and medium enterprises	157.17	196.41
iv) Other financial liabilities	108.44	177.18
b) Other current liabilities	217.31	265.66
c) Provisions	1.24	1.10
	920.81	1,138.95
	6,786.56	6,592.29
TOTAL EQUITY AND LIABILITIES		

for Jeevan Scientific Technology

K. Krishna Kishore
Vice Chairman & Managing Director
(DIN:00876539)



Place: Hyderabad.
Date:30 May 2024

Jeevan Scientific Technology Limited CIN:L72200TG1999PLC031016			
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.			
Statement of Consolidated Audited Cash Flows (Amount in Indian rupees lakhs, except share data and where otherwise stated)			
S.No	Particulars	For the year ended 31 March 2024	For the year ended 31 March 2023
A.	Cash flow from operating activities		
	Net Profit/(loss) before tax	(160.39)	(368.27)
	Adjustments for:		
	Depreciation and amortisation expenses	592.93	507.32
	Fair value (gain)/loss on financial assets measured at amortized cost, net	1.61	(4.68)
	Dividend received	(11.79)	(10.50)
	Interest received	(38.35)	(84.10)
	Net foreign exchange loss/(gain)	(2.81)	(2.85)
	Share based payments to employees	151.41	247.94
	Finance cost	96.80	97.21
	Operating profit before working capital changes	629.42	382.06
	Changes in working capital		
	Inventories	(21.83)	58.40
	Trade receivables	(58.12)	(404.36)
	Current and non current financial assets	218.99	237.73
	Other current and non current assets	(146.70)	75.78
	Trade payables	(50.84)	50.16
	Other financial liabilities	(68.73)	(149.88)
	Other liabilities	(48.36)	(112.04)
	Provisions	12.88	(503.02)
	Cash generated from operations before tax	466.70	(365.15)
	Taxes Paid	(177.50)	(275.37)
	Net cash from operating activity	289.19	(640.52)
B.	Cash flow from investing activities		
	Purchase of property, plant and equipment including capital advances and capital creditors	(1,202.90)	(816.28)
	Movement in other bank balances	-	5.24
	Dividend Received	11.79	10.50
	Acquisition of a subsidiary, net of cash acquired	-	23.35
	Interest received	38.35	84.10
	Net cash used in investing activity	(1,152.76)	(693.09)
C.	Cash flow from financing activity		
	Proceeds from /(Repayment) of non current borrowings	(171.36)	(71.21)
	Proceeds from /(Repayment) of non current borrowings	627.75	-
	Proceeds from /(Repayment) of current borrowings	(22.16)	(539.16)
	Interest paid	(96.80)	(97.21)
	Dividend paid	-	(183.62)
	Proceeds from issuance of Equity Shares (ESOPS Exercise)	-	42.88
	Repayment of principle portion of lease liability	(102.78)	(106.03)
	Net cash generated in financing activity	234.64	(954.35)
	Net increase in cash and cash equivalents (A+B+C)	(628.93)	(2,287.96)
	Cash and cash equivalents at the beginning of the year/period	683.38	2,971.33
	Cash and cash equivalents at the end of the year/period	54.45	683.38

Pale: Hyderabad
Date: 30 May 2024

for Jeevan Scientific Technology Limited

K. Krishna Kishore
Vice Chairman & Managing Director
(DIN:00876539)





**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF THE STANDALONE
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF JEEVAN SCIENTIFIC TECHNOLOGY
LIMITED**

Opinion

We have audited the accompanying Statement containing Standalone Financial Results of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED (the "Company"), for the year ended March 31, 2024 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- a. is presented in accordance with the requirements of Regulation 33 and 52 of the Listing Regulations; and
- b. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended March 31, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SA's") specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2024 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Standalone Financial Results

This Statement, which includes the Standalone financial results for the year ended March 31, 2024, is the responsibility of the Company's Board of Directors, and has been approved by them for the issuance. The Standalone financials results for the year ended March 31, 2024 has been compiled from the related audited standalone financial statements. This responsibility includes preparation and presentation of the





Standalone Financial Results for the quarter and year ended March 31, 2024 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the accompanying Statement, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2024 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve





collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 and 52 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Annual standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to





PAVULURI & Co.
CHARTERED ACCOUNTANTS
Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639
Email : mail@pavuluriandco.com

communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For PAVULURI & CO
Chartered Accountants
(Firm's Registration No. 012194S)

CA . N. RAJESH
Partner
(Membership No.223169)
UDIN: 24223169BKATCU2805



Place: Hyderabad
Date: May 30, 2024



**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF CONSOLIDATED
FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF JEEVAN SCIENTIFIC TECHNOLOGY
LIMITED**

Opinion

We have audited the accompanying Statement of Consolidated Financial Results of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED (the "Company") and its subsidiaries (the Company and its subsidiaries together referred to as the "Group"), for the quarter and year ended March 31, 2024 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

(i) includes the audited financial results of the subsidiary NAYAS LABORATORIES PRIVATE LIMITED

(ii) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations;

and

(iii) gives a true and fair view in conformity with the recognition and measurement laid down in the Indian Accounting Standards ("Ind AS") and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group for the quarter and year ended March 31, 2024.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Consolidated Financial Results

This Statement which includes Consolidated financial results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance





The Statement has been compiled from the audited interim condensed consolidated financial statements for the three month and year ended March 31, 2024. This responsibility includes preparation and presentation of the Consolidated Financial Results that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Ind AS, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Company, as aforesaid.

In preparing the Consolidated Financial Results, the respective Boards of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Boards of Directors either intend to liquidate their respective entities or to cease operations, or have no realistic alternative but to do so.


The respective Boards of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results as a whole, are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures





responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Results, including the disclosures, and whether the Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Consolidated Financial Results of which we are the independent auditors.

Materiality is the magnitude of misstatements in the Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Consolidated Financial Results.





PAVULURI & Co.
CHARTERED ACCOUNTANTS
Plot No.48, Flat No.301,
MICASA, Phase - I, Kavuri Hills,
Hyderabad - 500 033.
Ph : 040-2970 2638 / 2639
Email : mail@pavuluriandco.com

We communicate with those charged with governance of the Company and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

For PAVULURI & CO

Chartered Accountants

(Firm's Registration No. 012194S)

CA.N.RAJESH

Partner

(Membership No.223169)

UDIN: 24223169BKATCV7144



Place: Hyderabad

Date: May 30, 2024